Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial

被引：0
|
作者：
Ritchlin, Christopher [1 ]
Strand, Vibeke [2 ]
Ballerini, Rocco [3 ]
Chou, Richard C. [4 ]
Rozzo, Stephen [3 ]
Mendelsohn, Alan [3 ]
Kavanaugh, Arthur [5 ]
机构：
[1] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Div Allergy Immunol & Rheumatol, Rochester, NY USA
[2] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA
[3] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[4] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY USA
[5] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1525
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao, Yan
    Zhang, Jianzhong
    Yang, Bin
    Li, Jingyi
    Ding, Yangfeng
    Wu, Liming
    Zhang, Litao
    Wang, Jinyan
    Zhu, Xiaohong
    Zhang, Furen
    Tao, Xiaohua
    Li, Yumei
    Zhang, Chunlei
    Li, Linfeng
    Lu, Jianyun
    Diao, Qingchun
    Lu, Qianjin
    Man, Xiaoyong
    Li, Fuqiu
    Xia, Xiujuan
    Cheng, Hao
    Jia, Yingmin
    Zhao, Guoqing
    Yan, Jinchun
    Chen, Bo
    CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 200 - 208
  • [42] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao Yan
    Zhang Jianzhong
    Yang Bin
    Li Jingyi
    Ding Yangfeng
    Wu Liming
    Zhang Litao
    Wang Jinyan
    Zhu Xiaohong
    Zhang Furen
    Tao Xiaohua
    Li Yumei
    Zhang Chunlei
    Li Linfeng
    Lu Jianyun
    Diao Qingchun
    Lu Qianjin
    Man Xiaoyong
    Li Fuqiu
    Xia Xiujuan
    Cheng Hao
    Jia Yingmin
    Zhao Guoqing
    Yan Jinchun
    Chen Bo
    中华医学杂志英文版, 2024, 137 (02)
  • [43] Applicability of Press Needles to a Double-blind Trial A Randomized, Double-blind, Placebo-controlled Trial
    Miyazaki, Shougo
    Hagihara, Akihito
    Kanda, Ryo
    Mukaino, Yoshito
    Nobutomo, Koichi
    CLINICAL JOURNAL OF PAIN, 2009, 25 (05): : 438 - 444
  • [44] The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
    McMurray, John J. V.
    Freeman, Mason W.
    Massaro, Joe
    Solomon, Scott
    Lock, Paul
    Riddle, Matthew C.
    Halvorsen, Yuan-Di C.
    DIABETES, 2020, 69
  • [45] Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
    Mease, PJ
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SD
    Choy, EHS
    Sharp, JT
    Ory, PA
    Perdok, RJ
    Weinberg, MA
    ARTHRITIS AND RHEUMATISM, 2005, 52 (10): : 3279 - 3289
  • [46] A double-blind placebo-controlled randomised trial of pregabalin for alcohol dependence: interim analysis
    Krupitsky, E.
    Rybakova, K.
    Skurat, E.
    Kiselev, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S663 - S664
  • [47] Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti-Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Chohan, Saima
    Garcia Fructuoso, Ferran J.
    Gottlieb, Alice
    Chou, Richard C.
    Mendelsohn, Alan
    Ballerini, Rocco
    Luggen, Michael E.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [48] Chikungunya Arthritis Treatment with Methotrexate and Dexamethasone: A Randomized, Double-blind, Placebo-controlled Trial
    Amaral, Jose Kennedy
    Lucena, Gabriela
    Schoen, Robert Taylor
    CURRENT RHEUMATOLOGY REVIEWS, 2024, 20 (03) : 337 - 346
  • [49] Responder Rates to Atogepant in Patients With Episodic Migraine: A Post Hoc Analysis of Results From a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Dodick, David W.
    Ailani, Jessica
    Goadsby, Peter J.
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Li, Ye
    Szegedi, Armin
    CEPHALALGIA, 2019, 39 : 183 - 184
  • [50] Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Dodick, D. W.
    Ailani, J.
    Goadsby, P. J.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Li, Y.
    Szegedi, A.
    HEADACHE, 2019, 59 : 79 - 80
12345